Chronic traumatic encephalopathy

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

Retrieved on: 
onsdag, maj 22, 2024
CTE, Principal, Patient, Metabolism, Baylor College of Medicine, Emergency medicine, Phase, Human, JAMA Cardiology, Chronic traumatic encephalopathy, Traffic, TBI, Common, Concussion, Emergency department, Baylor University, Efficacy, Animal, Blood, NCE, Nasal cavity, Biomarker, Post-concussion syndrome, DSM-IV codes, Brain, Research, Cardiology, Acute coronary syndrome, Traumatic brain injury, Pharmaceutical industry

SARASOTA, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. William “Frank” Peacock as its Chief Clinical Officer, who will conduct its anticipated Phase II clinical trial for treating concussion in the Emergency Department (“ED”).

Key Points: 
  • SARASOTA, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. William “Frank” Peacock as its Chief Clinical Officer, who will conduct its anticipated Phase II clinical trial for treating concussion in the Emergency Department (“ED”).
  • Dr. Peacock is currently the Vice Chair for Emergency Medicine Research at Baylor College of Medicine and a past Professor at the Cleveland Clinic Lerner College of Medicine.
  • “I am excited to join Oragenics as its Chief Clinical Officer at such an important and pivotal time in the company’s clinical program.
  • We are currently working with Avance Clinical, CRO, for our Phase II trial,” stated Michael Redmond, President of Oragenics.

Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial

Retrieved on: 
torsdag, maj 16, 2024
CTE, Partnership, Traffic barrier, Disease, Patient, Metabolism, Phase, Inhalation, Human, Concussion, Chronic traumatic encephalopathy, Traffic, Trauma, Common, Absorption, Post-concussion syndrome, DSM-IV codes, Brain, Alzheimer's disease, Parkinson's disease, Contract research organization, GMP, Traumatic brain injury, Pharmaceutical industry

Oragenics is designing an upcoming Phase II clinical trial conducted in acute and emergency departments.

Key Points: 
  • Oragenics is designing an upcoming Phase II clinical trial conducted in acute and emergency departments.
  • The company is preparing to initiate a Phase II clinical trial for its lead drug candidate, ONP-002, an innovative neurosteroid designed to treat mild Traumatic Brain Injury (mTBI), commonly referred to as concussion.
  • Oragenics is focused on enhancing the formulation of ONP-002 by increasing the percentage of active compound in the final spray-dried intranasal powder.
  • In preparation for the Phase II clinical trial, Oragenics has secured an adequate supply of intranasal devices.

Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia

Retrieved on: 
tisdag, maj 7, 2024
Contract research organization, Brain, Traumatic brain injury, NCE, Common, Food and Drug Administration, Therapeutic Goods Administration, Food, Partnership, Science, TBI, Concussion, Incidence, Patient, CTE, Head Injuries, DSM-IV codes, Chronic traumatic encephalopathy, Clinical trial, European Medicines Agency, Traffic, Pharmaceutical industry

This trial aims to evaluate Oragenics' lead drug candidate, ONP-002, for mild Traumatic Brain Injury (TBI), commonly known as concussion.

Key Points: 
  • This trial aims to evaluate Oragenics' lead drug candidate, ONP-002, for mild Traumatic Brain Injury (TBI), commonly known as concussion.
  • An Oragenics Phase I clinical trial, recently completed in Australia under the management of Avance Clinical, demonstrated that ONP-002 is safe and well-tolerated.
  • "Concussion remains a significant unmet medical need," said Dr. Jorgen Mould, Senior Director of Scientific and Regulatory Services at Avance Clinical.
  • Michael Redmond, President of Oragenics, added, "Our collaboration with Avance Clinical during the Phase I trial was instrumental, and we are confident in their ability to execute an effective Phase II trial that will pave the way for future treatment protocols for concussion."

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Retrieved on: 
måndag, mars 18, 2024
Pharmaceutical, Health, Neurology, Clinical Trials, Depression, Metabolism, Brain, NCE, Acute stress disorder, Concussion, Veterans' affairs, Executive, Common, Inflammation, Patient, United States Congress, TBI, Foundation (nonprofit), Anxiety, CTE, University, Military personnel, Oxidative stress, Human, GMP, Nasal cavity, Traumatic brain injury, DSM-IV codes, Phase, Traffic, Swelling, FDA, Animal, Pentagon, Chronic traumatic encephalopathy, Phase II, Marcus Foundation, Medical device

Oragenics’ lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (TBI), aka concussion.

Key Points: 
  • Oragenics’ lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (TBI), aka concussion.
  • Dr. Kelly was also National Director of the Avalon Action Alliance TBI Programs for which the MIBH serves as the clinical coordinating center.
  • “I am excited to join Oragenics as its Chief Medical Officer at such an important and pivotal time in the drug development process.
  • Dr. Kelly has interacted with the FDA and clinical trials for brain injury throughout his esteemed career.

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Retrieved on: 
tisdag, mars 5, 2024
Pharmaceutical, Health, Clinical Trials, Mental Health, CTE, Nasal administration, Active ingredient, Metabolism, IIA, Traumatic brain injury, Concussion, API, Nasal cavity, Animal, GMP, Common, Traffic, Safety, Patient, DSM-IV codes, Phase, Chronic traumatic encephalopathy, NCE, Brain, Pharmaceutical industry

The drug candidate is expected to be combined with its novel intranasal device, for the treatment of mild Traumatic Brain Injury, aka concussion.

Key Points: 
  • The drug candidate is expected to be combined with its novel intranasal device, for the treatment of mild Traumatic Brain Injury, aka concussion.
  • A 40-patient Phase I human study showed ONP-002 to be safe and well-tolerated.
  • Phase II patients will be recruited between the ages of 18-55 in the acute phase following concussion.
  • “Preclinical intranasal targeting of the brain has been shown to improve outcomes in animals and safety margin following concussion.

MDK MOTORSPORTS ANNOUNCES ITS SUPPORT OF THE PROFESSIONAL ATHLETES BRAIN HEALTH STUDY

Retrieved on: 
torsdag, februari 29, 2024
CTE, Woman, Motorsport, F1, Formula, Education, USAC, Growth, Formula One, Learning, Risk, Sport, Safety, LE, Concussion, Brain damage, Knowledge, Brain, Trauma, Athlete, RHI, Research, Chronic traumatic encephalopathy, Dietary supplement

PATASKALA, Ohio, Feb. 29, 2024 /PRNewswire/ -- MDK Motorsports has launched a commitment to support research of the long-term effects of repetitive head impacts (RHI) in active and retired professional athletes through Cleveland Clinic Lou Ruvo Center for Brain Health's Professional Athletes Brain Health Study (PABHS).

Key Points: 
  • MDK Motorsports' support, both financially and with the referral of its athletes to participate in the study, marks an expansion of the program to include professional motorsports drivers and riders, signaling an important initiative for the burgeoning sport.
  • Notably, the United States Auto Club (USAC) and Porsche Motorsport North America have also announced their support for the PABHS, underscoring the motorsports industry's commitment to brain health.
  • The insights gained from motorsports have the potential to enhance long-term brain safety for professional drivers and athletes in other sports as well."
  • As a result, we are proud to support the work of the Professional Athletes Brain Health Study to further advance the cause."

Could flag football one day leapfrog tackle football in popularity?

Retrieved on: 
onsdag, februari 7, 2024
Chronic traumatic encephalopathy, Democrat, Obscurity, ABC, Bowl game, Social movement, Attention, Growth, CTE, Parent, Concussion, Research, Nike, International, Republican, Politics, News, Brain, Safety, Super Bowl, Athlete, Football, LeBron James, Sport, Gatorade, Basketball, Gold, Risk, Visa, ESPN, Culture, Student, Radar, NFL, Secondary school, Human, Pro Bowl, Sports equipment

Once a casual activity played at family reunions, the competitive sport of flag football is “soaring,” “exploding” and “skyrocketing in popularity nationwide,” according to mainstream news outlets.

Key Points: 
  • Once a casual activity played at family reunions, the competitive sport of flag football is “soaring,” “exploding” and “skyrocketing in popularity nationwide,” according to mainstream news outlets.
  • There’s some data behind the breathless headlines: According to the NFL’s official flag football program, since 2015 the number of kids ages 6 to 12 who play flag football has risen by 38%, to more than 1.5 million.
  • In my recent book, “Emerging Sports as Social Movements,” I explore nontraditional sports like flag football and disc golf.

A fun, fast, safer alternative

  • Though its rules are similar to tackle football, flag football is currently gaining attention for what makes it different.
  • A “tackle” involves snatching one of two flags that hang from the hips of the ball carrier.
  • While players face injury risks, they sustain far fewer head impacts than athletes who play tackle football.
  • With the public’s concerns about brain injuries on the rise, many parents are opting for flag football instead of tackle for their kids.

The NFL cultivates the grassroots

  • Although it may come as a surprise, the NFL is embracing flag football and taking its growth seriously.
  • In 2021, the NFL and Nike committed US$5 million in equipment to support high school flag football teams across the nation.
  • Most NFL teams are currently supporting the grassroots of flag football with summer camps, clinics and regional tournaments.

By the numbers

  • According to figures collected annually by the National Federation of High Schools, 21,980 students played high school flag football in 2023.
  • To put this number in context, however, tackle football attracted 47 times more students – roughly 1 million players – the same year.
  • Though high school participation in flag football has increased steadily since 2007, almost all the growth comes from the girls’ side.
  • A nationwide sports participation survey finds that the number of casual players of flag football is up, but core participation is down.

Red sport, blue sport

  • Over the past decade, several studies have found a link between repeated head impacts and the risk for serious brain injuries, including chronic traumatic encephalopathy, or CTE.
  • Yet recent efforts to make tackle football safer for young athletes have been met with fierce resistance from families, fans and organizers.
  • In many regions of the U.S., tackle football is deeply ingrained in the culture, leading to strong opposition to any changes.
  • As beliefs about the dangers of tackle football become polarized, the perceived benefits of flag football will likely follow suit.
  • As I showed in a recent study of sport popularity in 207 areas of the U.S., flag football is more popular in regions that tend to vote Democratic, with tackle football more popular in Republican areas.


Josh Woods does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Children’s high-impact sports can be abuse – experts explain why

Retrieved on: 
tisdag, februari 6, 2024
UNCRC, Concussion, CTE, Parent, Failure, Research, Myenteric plexus, Nottingham Trent University, NSPCC, United Nations Convention, Brain, Kevin Turner (running back), Head Injuries, Chronic traumatic encephalopathy, Head, Boxing, Injury, Brain damage, Accident, Abuse, Risk, Social skills, Smoking, Violence, Rights, Sport, Sociology, NFL, Sports equipment

CTE continues to be a serious risk associated with high impact sports, such as boxing, American football and rugby.

Key Points: 
  • CTE continues to be a serious risk associated with high impact sports, such as boxing, American football and rugby.
  • The NFL has paid out almost a million pounds to former players suffering the effects of sport-induced brain trauma.
  • Each additional year of playing impact sports raises the risk of CTE, by as much as 30% in American football.
  • Academic evidence and medical professionals now agree that sport-induced brain trauma leads to degenerative brain disease.

Not suitable for under-18s

  • We are not calling for adult versions of impact sports to be banned and our argument does not apply to sports or activities where brain trauma might occur by accident.
  • For example, heading a football can result in immediate and measurable alterations to brain functioning and longer-term brain diseases, such as CTE.
  • The risk of CTE is far higher in sports such as American football and rugby.

Staying healthy

  • Teams sports can reduce isolation and help players to develop a range of social skills.
  • There are no health benefits of tackling – and there are no health benefits of being struck in the head.
  • Research has shown that incidents of contact during children’s rugby are the cause of cause of 87% of known injuries.

Inability to consent

  • Children are unable to make informed decisions about the long-term risks of these activities.
  • Our research draws on a number of legal positions that support our argument that neither children nor parents on their behalf can consent to sports that require brain trauma as a necessary component of the sport.
  • Some commentators have agreed that while high-impact sports are dangerous, using the term child abuse is a step too far.
  • Read more:
    Sport-induced traumatic brain injury: families reveal the 'hell' of living with the condition


Keith Parry is affiliated with the Concussion Legacy Foundation (UK). Eric Anderson and Gary Turner do not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

Retrieved on: 
måndag, februari 5, 2024
Mental Health, Health, Neurology, Clinical Trials, General Health, Pharmaceutical, NCE, Memory, Concussion, CTE, Chronic traumatic encephalopathy, Traumatic brain injury, Nasal administration, Patient, Safety, Diagnosis, Brain, Animal, DSM-IV codes, Nasal cavity, Phase, Traffic, Common, Pharmaceutical industry

Oragenics has begun the final process of synthesizing and formulating the drug needed for its Phase II clinical trial.

Key Points: 
  • Oragenics has begun the final process of synthesizing and formulating the drug needed for its Phase II clinical trial.
  • We are excited to get the Phase II clinical trials underway,” commented Dr. James “Jim” Kelly, Neurologist and Executive Director of the Marcus Institute of Brain Health and an advisor on the planned phase II trial.
  • The drug has a large safety margin between dosages used in the animal toxicology program and those used in the Phase I study and planned for the upcoming Phase II clinical trial.
  • Post concussion syndrome is linked to long term disability and occurs in as high as 20% of concussed patients.

KBR Teams with HJF, Awarded Critical Contract to Aid Military Neuroscience Research

Retrieved on: 
måndag, december 18, 2023
Research, NYSE, Military medicine, Force, Health, UCSF, NASA, HJF, Chronic traumatic encephalopathy, Therapy, Medical research, University, HHPC, Brain damage, Growth, Knowledge, Military personnel, CTE, Military, SPARC, Energy Savings Performance Contract, Education, KBR, Nursing, Family

HOUSTON, Dec. 18, 2023 /PRNewswire/ -- KBR (NYSE: KBR) is pleased to join forces with The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) on an important contract to support neuroscience research for service members.

Key Points: 
  • HOUSTON, Dec. 18, 2023 /PRNewswire/ -- KBR (NYSE: KBR) is pleased to join forces with The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) on an important contract to support neuroscience research for service members.
  • Research will be done in collaboration with the Uniformed Services University (the nation's only federal health sciences university), and the University of California San Francisco (UCSF).
  • Under the terms of the Service Personnel Advancing Research in Chronic Traumatic Encephalopathy (SPARC) contract, KBR will provide outreach, education and data analytics to support critical neuroscience research for the prevention and treatment of military members with chronic traumatic encephalopathy (CTE).
  • KBR also continues to collaborate with the Airmen Readiness and Medical Research (ARMR) contract on various brain scanning and neuroimaging projects.